Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$482.27 USD

482.27
956,306

-6.51 (-1.33%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $482.44 +0.17 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (178 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Globus Medical (GMED) Gains on Innovation, Strategic Deal

by Zacks Equity Research

Globus Medical's (GMED) Enabling technology sales improvement is driven by strong performance of its robotic and imaging system.

Here's Why You Should Retain Bruker (BRKR) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Bruker (BRKR) based on the strong performances of the Bruker BioSpin Group.

McKesson (MCK) to Report Q1 Earnings: Is a Beat in Store?

by Zacks Equity Research

McKesson's (MCK) fiscal first-quarter 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

BD (BDX) Gears Up for Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited Q3 sales.

CVS Health (CVS) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

We expect brand price inflation, new product launch, higher utilization and new PBM clients to have contributed to second-quarter growth for CVS Health (CVS).

Sumit Singh headshot

Pick These 4 Stocks With Superb Interest Coverage Ratio

by Sumit Singh

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Lincoln Electric (LECO), McKesson (MCK), Atmos Energy (ATO) and O'Reilly (ORLY) are sound enough to meet financial obligations.

Henry Schein (HSIC) Set to Post Q2 Earnings: What Awaits?

by Zacks Equity Research

Henry Schein's (HSIC) second-quarter 2023 results are likely to be aided by the Dental business and new buyouts.

Ecolab (ECL) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) second-quarter results are likely to reflect continued segmental strength.

Lantheus (LNTH) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Lantheus' (LNTH) second-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.

McKesson (MCK) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Is a Beat Likely for AmerisourceBergen (ABC) in Q3 Earnings?

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal third-quarter 2023 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

Stryker (SYK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Stryker's (SYK) second-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.

Bio-Rad Laboratories (BIO) to Post Q2 Earnings: What Awaits?

by Zacks Equity Research

Bio-Rad Laboratories' (BIO) second-quarter 2023 results are likely to reflect an impressive performance across its Clinical Diagnostics business.

DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) second-quarter 2023 results are likely to reflect rising volumes across all channels.

What's in Store for West Pharmaceutical (WST) in Q2 Earnings?

by Zacks Equity Research

West Pharmaceutical's (WST) second-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.

STERIS (STE) Set to Post Q1 Earnings: What's in the Cards?

by Zacks Equity Research

STERIS' (STE) first-quarter fiscal 2024 results are likely to reflect an impressive performance across the Healthcare and AST segments.

GE HealthCare (GEHC) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

GE HealthCare's (GEHC) Imaging revenue growth in Q2 is expected to have been led by Magnetic Resonance as well as its molecular imaging entity.

Baxter (BAX) to Post Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Baxter's (BAX) second-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.

Intuitive Surgical (ISRG) Q2 Earnings Beat, Procedures Robust

by Zacks Equity Research

Intuitive Surgical's (ISRG) second-quarter results reflect healthy demand for procedures, partially offset by unfavorable currency. COVID-19 impacts procedure volume in China.

IDEXX Laboratories (IDXX) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

IDEXX Laboratories' (IDXX) second-quarter 2023 results are expected to reflect an impressive performance in the CAG segment.

Abbott (ABT) Q2 Earnings & Revenues Beat Estimates, Down Y/Y

by Zacks Equity Research

Abbott (ABT) delivers better-than-expected earnings and revenues in the second quarter of 2023

Intuitive Surgical (ISRG) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Intuitive Surgical's (ISRG) second-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.

Are Medical Stocks Lagging HealthEquity (HQY) This Year?

by Zacks Equity Research

Here is how HealthEquity (HQY) and McKesson (MCK) have performed compared to their sector so far this year.

Align Technology (ALGN) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Align Technology's (ALGN) second-quarter 2023 results are likely to highlight sustained stability across its Clear Aligner business.